NASDAQ · Biotechnology

DWTX (DWTX) Stock

$1.81 +3.14% NASDAQ: DWTX Healthcare

Valuation

MetricValue
Price$1.81
Market Cap$3.45M
P/E Ratio1.42
P/B Ratio0.66
P/S Ratio0.00
EPS (TTM)$-4.32
52-Week High$9.50
52-Week Low$1.28
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-34.67%
ROA-18.60%
ROCE-37.33%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio2.67

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-16.0M$-12.0M$-5.0M$-12.0M$-28.0M
Net Profit$-16.0M$-12.0M$-5.0M$-12.0M$-34.0M
EPS$-47.90$-27.66$-7.05$-12.52$-4.32
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$16.0M$8.0M$4.0M$94.0M$90.0M
Total Liabilities$1.0M$1.0M$0$30.0M$15.0M
Cash$14.0M$7.0M$3.0M$15.0M$7.0M
Borrowings$0$0$0$16.0M$0

Latest News

Dogwood Therapeutics Enrolls First 200 Patients in Phase 2b Neuropathic Pain Trial MT Newswires · Jul 20, 2026 Dogwood Enrolls First 200 Patients in Ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathy Trial; Top-line Data Expected in Fall 2026 GlobeNewswire · Jul 20, 2026 Dogwood Therapeutics Appoints Iain Dukes, Venture Partner at OrbiMed, as Chair of Scientific Advisory Board GlobeNewswire · Jun 30, 2026 Chemotherapy-Induced Peripheral Neuropathy Market to Witness Significant Growth at a CAGR of 14.2% During the Forecast Period (2026-2036) as Novel Therapies Enter Late-Stage Development | DelveInsight PR Newswire · Jun 16, 2026 Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study GlobeNewswire · May 18, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-16.0M$-11.0M$-5.0M$-9.0M$-16.0M
Investing Cash Flow$0$0$0$4.0M$0
Financing Cash Flow$0$0$0$0$0
Net Cash Flow$-16.0M$-7.0M$-4.0M$12.0M$-8.0M
Free Cash Flow$-16.0M$-11.0M$-5.0M$-9.0M$-16.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA-1.35
FCF Yield-510.85%
Quick Ratio5.86
Interest Coverage—
Return 1Y-69.36%
Return 3Y-97.62%
Return 5Y-98.99%

Ownership

Insiders Held73.35%
Institutions Held10.97%
Institutions Float Held41.17%
Institutional HolderSharesReport Date
Armistice Capital, LLC3,280,0002026-03-31
Vanguard Capital Management LLC132,1542026-03-31
Geode Capital Management, LLC79,4342026-03-31
Vanguard Fiduciary Trust Co62,7362026-03-31
Northern Trust Corporation23,7792026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BOLT $3.95 -0.50% -0.26 $7.59M 0.00%
BRTX $0.20 -2.11% -0.33 $1.83M 0.00%
CLRB $2.37 -2.07% -0.38 $7.57M 0.00%
COCP $0.92 +0.14% -1.46 $12.68M 0.00%
EDSA $5.35 +1.90% -8.61 $51.54M 0.00%

About DWTX

DWTX is led by CEO Gregory Duncan, employs 12 people, headquartered in US, publicly traded since 2020.

DWTX stock trades at $1.81 with a market capitalization of $3.45M. The stock is valued at a price-to-earnings (P/E) ratio of 1.42, price-to-book of 0.66, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.28 and $9.50, and currently trades 80.9% below its 52-week high.

On profitability, DWTX generates a return on equity (ROE) of -34.67%, return on capital employed of -37.33%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides